



This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of Precautions Indapamide

July 7, 2015

Non-proprietary name

Indapamide

Safety measure

Precautions should be revised in the package insert.

In the Clinically significant adverse reactions subsection of the Adverse reactions section, the following text should be revised (underlined parts are revised):

Toxic epidermal necrolysis (TEN), oculomucocutaneous syndrome (Stevens-Johnson syndrome), and erythema multiforme exudativum:

Toxic epidermal necrolysis, oculomucocutaneous syndrome, or erythema multiforme exudativum may occur. Patients should be carefully monitored. If any abnormalities such as erythema, pruritus, or enanthema are observed, administration of this drug should be discontinued, and appropriate measures should be adopted.

NOTE

- This drug is designated to prepare a Drug Guide for Patients.